Keyword: Mayzent (siponimod)
Multiple sclerosis drug Ocrevus is hailed as the most successful launch in Roche’s history, earning blockbuster status in its first 12 months.
New Mayzent data could help Novartis build the case for early treatment in secondary progressive MS, a market it's currently working to crack.
Novartis kept things busy in 2019 as it continued to focus on becoming a top medicines company. It spun off eye care medtech business Alcon, and at the same time bought legacy Shire’s Xiidra to boost its ophthalmic drug franchise and acquired The Medicines Company for cholesterol-lowering med inclisiran.
Amid federal kickback charges, Novartis escaped a yearslong whistleblower lawsuit alleging it paid doctors to boost scripts of MS blockbuster Gilenya.
Competing with multiple blockbusters in multiple sclerosis, Merck KGaA's Mavenclad is making a name for itself with skyrocketing sales.
A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.
Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.
A post hoc analysis found 75% of patients showed no increase in disability five years after treatment with Mavenclad.